ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, Inc., which develops first-in-class drug therapies to treat eye diseases, initiated a Phase 2 Clinical Trial for the treatment of macular edema following non-infectious uveitis.